JAGUAR HEALTH, INC. Notes Payable, Noncurrent
JAGUAR HEALTH, INC. (JAGX) had Notes Payable, Noncurrent of $1.73 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermNotesPayable · last filed 2026-08-19
- 2026-06-30: Notes Payable, Noncurrent $1.73M.
- 2026-03-31: Notes Payable, Noncurrent $11.07M.
- 2025-12-31: Notes Payable, Noncurrent $15.08M.
- 2025-09-30: Notes Payable, Noncurrent $7.65M.
| Period end | Notes Payable, Noncurrent |
|---|---|
| 2026-06-30 | $1.73M 10-Q · filed 2026-08-19 |
| 2026-03-31 | $11.07M 10-Q · filed 2026-05-20 |
| 2025-12-31 | $15.08M 10-Q · filed 2026-08-19 |
| 2025-09-30 | $7.65M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $10.74M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $18.43M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $23.50M 10-K · filed 2026-04-07 |
| 2024-09-30 | $21.66M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $21.81M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $21.72M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $30.99M 10-K · filed 2025-03-31 |
| 2023-09-30 | $31.16M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $16.85M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $17.54M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $17.74M 10-K · filed 2024-04-01 |
| 2022-09-30 | $20.01M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $23.36M 10-Q · filed 2022-08-22 |
| 2022-03-31 | $24.78M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $25.02M 10-K · filed 2023-03-24 |
| 2021-09-30 | $24.93M 10-Q · filed 2021-11-17 |
| 2021-06-30 | $24.20M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $24.23M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $12.42M 10-K · filed 2022-03-11 |
| 2020-09-30 | $2.66M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $400.00K 10-Q · filed 2020-08-13 |
| 2020-03-31 | $400.00K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $450.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | $6.68M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $7.76M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |